-
Mashup Score: 11
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program Development funding agreement to provide up to $150 million to offset program costs and to accelerate clinical research for Teva’s TEV-‘248 program in line with Teva’s Pivot to Growth strategy to step up innovation and advance its innovative pipeline Teva’s TEV-‘248 has the potential to be the first Dual-Action Asthma Rescue Inhaler combining an Inhaled Corticosteroid with a Short-Acting Beta-Agonist (ICS-SABA) for both adult and pediatric asthma indications Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 12
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest grossing pharmaceutical products in the world, with sales in the U.S. of
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Today, the FDA approved an interchangeable #biosimilar that may provide broader access to needed medicines for patients with autoimmune diseases. Along with our partner @alvotechpr, we are proud of this milestone with more to come. Read more: https://t.co/g4EfN7BnQB #TevaUSA https://t.co/n8tK8b2bKl
-
-
Mashup Score: 2Teva Reports Growth in Fourth Quarter and Full Year 2023 - 11 month(s) ago
2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO ® – exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY ® – global annual revenues of $435 million, up 16% from 2022; Generics business continues to stabilize, back to revenue growth Q4 2023 and full year 2023 figures include the impact of the $500 million upfront payment received in connection with the collaboration on our anti-TL1A asset Ongoing net debt reduction – reduced to $16.6 billion as of December 31, 2023 Pivot to Growth strategy in action : Teva api Intended divestiture will allow us to focus on our core business strengths and capital allocation towards growth engines and innovation Exclusive collaboration with Sanofi on anti TL1-A (TEV-‘574) entered into in October 2023 Funding agreement with Royalty Pharma on olanzapine LAI (TEV-’749) License agreement with Biolojic
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2023 business results. https://t.co/RZ6UsL39sy Forward-looking statements are subject to the cautionary note included in our Q3 2023 press release. #QuarterlyResults #Earnings $Teva https://t.co/x4OToz7Qx1
-
-
Mashup Score: 2Teva Reports Growth in Fourth Quarter and Full Year 2023 - 11 month(s) ago
2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO ® – exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY ® – global annual revenues of $435 million, up 16% from 2022; Generics business continues to stabilize, back to revenue growth Q4 2023 and full year 2023 figures include the impact of the $500 million upfront payment received in connection with the collaboration on our anti-TL1A asset Ongoing net debt reduction – reduced to $16.6 billion as of December 31, 2023 Pivot to Growth strategy in action : Teva api Intended divestiture will allow us to focus on our core business strengths and capital allocation towards growth engines and innovation Exclusive collaboration with Sanofi on anti TL1-A (TEV-‘574) entered into in October 2023 Funding agreement with Royalty Pharma on olanzapine LAI (TEV-’749) License agreement with Biolojic
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2023 business results. https://t.co/RZ6UsL39sy Forward-looking statements are subject to the cautionary note included in our Q3 2023 press release. #QuarterlyResults #Earnings $Teva https://t.co/x4OToz7Qx1
-
-
Mashup Score: 4
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.At Teva Pharmaceutical Industries Ltd.,…
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Tune in today at 8:15am PT (11:15am ET) to hear our presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Teva CEO Richard Francis will discuss Teva's #PivotToGrowth strategy, business performance and plans ahead. Join here: https://t.co/T2WJ5Djq1j #JPM2024 $Teva https://t.co/xX3sd8rl5Y
-
-
Mashup Score: 3
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.At Teva Pharmaceutical Industries Ltd.,…
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
We're coming to #JPM2024! Tune in live on Monday, Jan 8, at 8:15am PT, as Teva CEO Richard Francis and the leadership team will discuss Teva's #PivotToGrowth strategy, business performance, and plans ahead. Tune in here: https://t.co/4L6EoZkIXt #JPM #Tevapharm https://t.co/cPv8IuWZmK
-
-
Mashup Score: 0Teva Pharmaceutical Industries Ltd. - Q3 2023 Teva Pharmaceutical Industries Ltd. Earnings Conference Call - 1 year(s) ago
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.At Teva Pharmaceutical Industries Ltd.,…
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Tune in live: Our Q3 2023 earnings call is starting in 30 minutes. Join CEO Richard Francis and the Teva leadership team live, as they discuss Teva's business performance and plans ahead. Join here: https://t.co/o7w2CSn5P9 #QuarterlyResults #Earnings $Teva https://t.co/Fu7vGABQDM
-
-
Mashup Score: 6Teva Reports Fourth Quarter and Full Year 2019 Financial Results - 5 year(s) ago
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005398/en/ Full-Year 2019 and Q4 2019 Highlights : FY 2019 Q4 2019 Revenues $16.9 billion $4.5 billion Revenues prior to revision (*) $17.5 billion…
Source: ir.tevapharm.comCategories: Healthcare ProfessionalsTweet-
$TEVA is attributing its good performance in the quarter to the launch of its biosimilar Rituxan, Truxima, in the U.S. That seems newsworthy given how biosimilars have struggled to penetrate the American market. https://t.co/TZsZi7XEBz
-
Today Teva announced a clinical collaboration agreement with Launch Therapeutics and a strategic funding development agreement with @Abingworthbio to accelerate development of our dual-action asthma rescue inhaler respiratory program. Read more: https://t.co/0KqB2lyypD #Asthma https://t.co/ZdDurPB4dt